What Nanoscope Therapeutics does

Nanoscope Therapeutics, Inc. is a privately held, late-stage clinical biotechnology company headquartered in Dallas, Texas, developing disease-agnostic, mutation-agnostic optogenetic gene therapies for retinal degenerative diseases. The company's core technology is the proprietary Multi-Characteristic Opsin (MCO) platform, which delivers light-sensitive opsins to bipolar retinal cells so they become photosensitive, bypassing degenerated photoreceptors without requiring genetic testing, invasive surgery, or repeat dosing. Its lead asset, MCO-010 (brand name MOGENRY; INN: sonpiretigene isteparvovec), is an AAV-delivered, one-time intravitreal therapy advancing through a rolling Biologics License Application to the FDA for retinitis pigmentosa (RP), with a Phase 2 trial completed in Stargardt disease (STARLIGHT) and a Phase 3 planned. A non-viral, laser-delivered second asset, MCO-020, targets geographic atrophy (GA) with a Phase 2 program expected in 2026, and an IND-ready Leber congenital amaurosis (LCA) program extends the pipeline.

Nanoscope's business model is one-time gene therapy administration — a single intravitreal injection administered by retinal specialists in-office, reimbursed at premium gene-therapy pricing once approved. The company has secured US distribution through InspiroGene by McKesson for specialty pharmacy, distribution, and patient hub services post-approval. Revenue is not yet recognized (pre-commercial); the company funds operations through venture capital, a disclosed $1.5M NIH SBIR grant (2021), and the implicit assumption of subsequent un-disclosed financing rounds. Currently 11-50 employees, it is rapidly scaling a commercial leadership bench (COO Paul Hallen from Alcon; CFO Michael Marquez; SVP Sales & Marketing Ashish Patel; SVP Regulatory & Quality Khandan Baradaran).

The company's competitive position rests on a broad patent estate (US Patent No. 12459977 through 2039, plus corresponding patents in Australia and Japan and pending applications in China and EU; co-founder/CSO Samarendra Mohanty holds 200+ international patents), a multi-jurisdiction regulatory footprint (FDA Fast Track, Orphan Drug, and RMAT designations; Japan MHLW Sakigake and Orphan Drug — a first for a retinal gene therapy; five EMA Orphan designations; Saudi Arabia Orphan), and durable clinical data (REMAIN 152-week follow-up showing ~0.3 LogMAR sustained visual acuity gain with no serious adverse events). Markets served include RP (~100,000 US patients, 25,000+ legally blind), Stargardt disease (~41,000 US patients, 1M+ worldwide), GA, and LCA, with regulatory pre-commercialization work underway across US, Japan, EU, and Saudi Arabia.

Name

Nanoscope Therapeutics

Legal name

Nanoscope Therapeutics, Inc.

Website

https://nanostherapeutics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Nanoscope Therapeutics is a Dallas-based, pre-commercial clinical-stage biotech developing disease-agnostic optogenetic gene therapies (Multi-Characteristic Opsin platform) to restore vision in patients with retinal degenerative diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.

Ownership category

akta.pro rank

Product category

Ophthalmic Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Ophthalmology Disorder Therapies (HLAIAIAK), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• Optogenetic gene therapy
• Retinal degenerative diseases
• Vision restoration therapy
• Ophthalmic biologics
• Mutation-agnostic therapy

Headquarters

HQ city

Bedford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue / Pre-commercialization stage: Nanoscope Therapeutics is pre-commercial with no product revenue; lead asset MCO-010 (brand name MOGENRY) is advancing through regulatory submission with rolling BLA initiated with FDA. Future revenue model will be one-time gene therapy administration (intravitreal injection) for retinal degenerative diseases, sold through specialty pharmacy and distribution channels (InspiroGene by McKesson).

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Core offering

Nanoscope Therapeutics develops disease-agnostic, mutation-agnostic optogenetic gene therapies using its proprietary Multi-Characteristic Opsin (MCO) platform to restore vision in patients with retinal degenerative diseases such as Retinitis Pigmentosa (RP), Stargardt Disease (SD), Geographic Atrophy (GA), and Leber Congenital Amaurosis (LCA). The lead asset MCO-010 (MOGENRY; INN: sonpiretigene isteparvovec) is a one-time, in-office intravitreal AAV-delivered gene therapy with a rolling BLA submission underway for RP, while MCO-020 is a non-viral laser-delivered optogenetic therapy in preclinical development for GA.

Product overview

Nanoscope Therapeutics offers a unified optogenetic therapy platform centered on its proprietary Multi-Characteristic Opsin (MCO) technology for vision restoration in patients with retinal degenerative diseases. The platform architecture consists of the core MCO Platform (broadband, fast response, ultra-sensitive optogenetic technology) supporting distinct therapeutic products including the lead MCO-010 (MOGENRY) AAV-delivered therapy for retinitis pigmentosa and Stargardt disease, and the non-viral MCO-020 therapy in development for geographic atrophy. Additional IND-ready programs include Leber congenital amaurosis (LCA). The MCO Platform enables disease-agnostic treatment through a single intravitreal injection approach that activates bipolar retinal cells to become light-sensitive without requiring genetic testing, supported by the MLSDT functional vision assessment tool used in clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• MOGENRY: Trade name for MCO-010, the company's lead optogenetic gene therapy asset being advanced for retinitis pigmentosa toward FDA approval.
• MCO Platform
• MCO-010

Products and services

• MCO-010 (MOGENRY) One-time, in-office, intravitreal disease-agnostic AAV-delivered optogenetic gene therapy that activates bipolar retinal cells to become light-sensitive, restoring vision in patients with photoreceptor degeneration. Lead asset in rolling BLA for Retinitis Pigmentosa and in Phase 2 STARLIGHT trial for Stargardt Disease.
• MCO-020 Non-viral optogenetic therapy using laser-delivered gene therapy for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. Currently in preclinical development with biodistribution data demonstrated in primates.

Quantifiable outcome

• ~0.3 LogMAR visual acuity gain sustained over 152 weeks (3 years) in REMAIN study with no serious adverse events
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered minor, flagship and core.

• Women In Bio (WIB)minorGTM or Marketing Partner · 22 June 2026CEO Sulagna Bhattacharya participating as a speaker in a Women In Bio (WIB) executive leadership panel discussion at the 2026 BIO International Convention titled 'Building Resilient Organizations in an Era of Uncertainty' alongside CEOs and senior leaders across science, capital, and organizational transformation.
• InspiroGene by McKessonflagshipChannel Partner/ Reseller/ Distributor · 27 May 2026Selected InspiroGene by McKesson to provide U.S. commercialization services for Nanoscope's lead product MOGENRY (MCO-010), subject to FDA approval. InspiroGene will support U.S. distribution through specialty pharmacy, specialty distribution, and patient hub services focused on US commercialization and supply chain. The collaboration positions Nanoscope to launch the first optogenetic gene therapy for the U.S. market, providing best-in-class experience for patients and providers. Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson, is the named counterpart; engagement initiated under COO Paul Hallen and CEO Sulagna Bhattacharya.
• Verana HealthcoreStrategic or Co-development Partner · 25 February 2025Verana Health and Nanoscope Therapeutics announced a collaboration to accelerate retinitis pigmentosa research. Verana Health provides real-world data and clinical research insights leveraging its specialty data networks and AI capabilities, while Nanoscope brings its MCO optogenetic therapy pipeline for RP. The collaboration is positioned to advance understanding of RP patient populations and support clinical development and commercialization planning.
• Max Planck Society (Max Planck Institute)coreOEM/ Whitelabel/ Licensing Partner · 30 September 2024Nanoscope Therapeutics licensed optogenetic catch technology from the Max Planck Society. The licensing arrangement covers proprietary optogenetic catch technology originating from the Max Planck Institute, providing Nanoscope with foundational IP rights for its MCO platform and extending its technology base. Disclosed September 30, 2024.
• Max Planck Society (Optogenetic Catch Technology)coreOEM/ Whitelabel/ Licensing Partner · 30 September 2024Already captured above under Max Planck Society — included once per partner to avoid duplication.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• GenSight Biologics: Closest direct competitor: French clinical-stage biotech developing optogenetic gene therapy (GS030, AAV2-based ChRtdimR opsin via AAV2 intravitreal injection with wearable goggles) for retinitis pigmentosa. Same optogenetic therapeutic approach targeting retinal ganglion cells via AAV delivery, and most advanced competing optogenetic program globally.
• Adverum Biotechnologies: Clinical-stage gene therapy company developing ixoberogene soroparvovec (Ixo-vec) for wet AMD and diabetic macular edema. Similar ophthalmology gene therapy pipeline structure, AAV-based delivery, retina specialist customer base, and U.S. clinical-stage status.
• MeiraGTx: Clinical-stage gene therapy company with ophthalmology programs including botaretigene sparoparvovec (AAV-RPGR) for X-linked retinitis pigmentosa, developed with Janssen. Direct overlap in RP gene therapy development and AAV intravitreal delivery.
• Regenxbio: Clinical/commercial-stage AAV gene therapy company with ABBV-RGX-314 for wet AMD and diabetic retinopathy, developed with AbbVie. Overlapping AAV delivery platform, retina specialist customer base, and gene therapy pipeline structure.
• Spark Therapeutics: Acquired by Roche; developed and commercializes voretigene neparvovec (Luxturna), the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65). Reference benchmark for retinal gene therapy pricing, distribution, and regulatory pathway that Nanoscope must navigate.

Emerging players

• Atsena Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases including Leber congenital amaurosis (LCA1) and X-linked retinitis pigmentosa (XLRP). Overlapping RP/LCA patient population and AAV delivery modality, with Phase 1/2 readouts expected.
• Editas Medicine: Clinical-stage CRISPR-based gene editing company developing EDIT-101 for LCA10 (Leber congenital amaurosis type 10) and EDIT-301 for sickle cell disease. Partial overlap in LCA indication with Nanoscope's LCA program and shared ophthalmology gene therapy focus.
• Coave Therapeutics: French clinical-stage gene therapy company developing AAV-based therapies for retinal degenerative diseases including RP and Stargardt disease. Direct disease-area overlap and emerging pipeline positioning relative to Nanoscope's MCO-010.
• Applied Genetic Technologies Corporation (AGTC): Clinical-stage AAV gene therapy company developing therapies for inherited retinal diseases including X-linked retinitis pigmentosa. Earlier-stage peer with similar retinal gene therapy pipeline structure and AAV-based delivery.

Broad incumbents

• Alcon: Largest dedicated ophthalmology medical device and pharmaceutical company, employer of Nanoscope's COO Paul Hallen and CFO Michael Marquez. Alcon provides broad retinal surgery, IOL, and pharmaceutical products and represents both a competitor in retinal care and the dominant acquirer/employer of senior retinal commercial talent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/NSTherapeutics
• Facebookfacebook.com/nanoscopetherapeutics
• LinkedInlinkedin.com/company/nanoscope-therapeutics-inc
• Instagraminstagram.com/nanoscopetherapeutics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanoscope Therapeutics